Related Experiment Video
Updated: Mar 9, 2026
04:03
Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
Published on: September 27, 2024
1.6K
The role of complement activation in COPD exacerbation recovery
John-Paul Westwood1, Alexander J Mackay2, Gavin Donaldson3
1Haemostasis Research Unit, University College London, London, UK.
ERJ Open Research
|January 6, 2017
Summary
Higher levels of sputum complement fragments (C3a, C5a) during chronic obstructive pulmonary disease (COPD) exacerbations correlate with longer recovery times. This finding may help predict recovery duration in COPD patients.
Area of Science:
- Pulmonology
- Immunology
- Biochemistry
Background:
- Chronic obstructive pulmonary disease (COPD) exacerbations are characterized by inflammation.
- Complement system activation is implicated in inflammatory processes.
- Sputum biomarkers may offer insights into COPD exacerbation severity and outcomes.
Purpose of the Study:
- To investigate the association between sputum levels of complement anaphylatoxins, specifically C3a and C5a, and the recovery time following COPD exacerbations.
- To determine if these complement fragments can serve as predictive markers for recovery duration.
Main Methods:
- Prospective observational study involving patients experiencing COPD exacerbations.
- Measurement of sputum complement fragments (C3a, C5a) using enzyme-linked immunosorbent assays (ELISA).
- Correlation analysis between complement fragment levels and clinical recovery parameters, including time to symptom resolution and return to baseline function.
Main Results:
- Sputum levels of both C3a and C5a were significantly elevated during COPD exacerbations compared to stable periods.
- A positive correlation was observed between higher concentrations of sputum C3a and C5a and longer recovery times.
- Patients with the highest quartile of complement fragment levels experienced the most prolonged recovery.
Conclusions:
- Sputum complement anaphylatoxins (C3a, C5a) are elevated during COPD exacerbations.
- These elevated levels are associated with a prolonged recovery period.
- Sputum C3a and C5a may serve as potential biomarkers for predicting recovery time in COPD exacerbations.
Related Concept Videos
01:27Complement System
11.5K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
11.5K
01:20COPD: Pathogenesis and Clinical Features
2.0K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.0K
01:26COPD: Management Using Bronchodilators and Corticosteroids
1.0K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.0K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
5.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
5.0K
01:24Chronic Obstructive Pulmonary Disease
2.8K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.8K
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.3K